Taft Acts as Legal Counsel to Advanced NanoTherapies in Strategic Investment

Taft is pleased to have acted as legal counsel to Advanced NanoTherapies (ANT) in a $4 million Series A extension from a prominent undisclosed strategic medical device company. The investment will be used for ANT’s clinical programs and to accelerate the path toward U.S. IDE approval for the SirPlux Duo Drug-Coated Balloon.

ANT is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery. Read the release here.

Taft’s legal team included Brandi Weekley and Abe Wehbi.

In This Article

You May Also Like